Matthew Herper

Forbes reporter covering science and medicine

Categories
N/A
Content Types
N/A
More Information
Location|Languages
Publications

Published Content

144
The Agonizingly Slow Progress Against The Cancer That Killed Aretha Franklin
forbes.comArticle
The Agonizingly Slow Progress Against The Cancer That Killed Aretha Franklin
August, 16 2018
A Harvard Scientist Thinks He Has a Gene Test for Heart Attack Risk. He Wants to Give It Away Free.
forbes.comArticle
A Harvard Scientist Thinks He Has a Gene Test for Heart Attack Risk. He Wants to Give It Away Free.
August, 13 2018
Alnylam Prices First Gene Silencing Drug At $450,000 Per Patient, But Offers Money-Back Guarantee
forbes.comArticle
Alnylam Prices First Gene Silencing Drug At $450,000 Per Patient, But Offers Money-Back Guarantee
August, 10 2018
RegenXBio Gene Therapy Shows Early Promise Eye Disease; Cholesterol Treatment Results Mixed
forbes.comArticle
RegenXBio Gene Therapy Shows Early Promise Eye Disease; Cholesterol Treatment Results Mixed
August, 8 2018
Regeneron And Bluebird Team To Invent New Cell Therapies For Cancer
forbes.comArticle
Regeneron And Bluebird Team To Invent New Cell Therapies For Cancer
August, 6 2018
Positive Results For Ovid Drug, But Questions Remain
forbes.comArticle
Positive Results For Ovid Drug, But Questions Remain
August, 6 2018
23andMe Gets $300 Million Boost From GlaxoSmithKline To Develop New Drugs
forbes.comArticle
23andMe Gets $300 Million Boost From GlaxoSmithKline To Develop New Drugs
July, 25 2018
Biotech Entrepreneur, 29, Raises $32 Million To Use AI To Develop Drugs For Parkinson's, ALS
forbes.comArticle
Biotech Entrepreneur, 29, Raises $32 Million To Use AI To Develop Drugs For Parkinson's, ALS
July, 16 2018
Trump Phones, And Pfizer Reverses Price Hikes. But Why?
forbes.comArticle
Trump Phones, And Pfizer Reverses Price Hikes. But Why?
July, 11 2018
George Church, CRISPR Pioneer, Embraces Alternative Tech In Project To Recode A Human Genome
forbes.comArticle
George Church, CRISPR Pioneer, Embraces Alternative Tech In Project To Recode A Human Genome
May, 1 2018
This Startup Has a New CRISPR Enzyme -- And Says It Will Give It Away For Free
forbes.comArticle
This Startup Has a New CRISPR Enzyme -- And Says It Will Give It Away For Free
December, 13 2017
Scientists Could Cure Hemophilia With Gene Therapy. For Real.
forbes.comArticle
Scientists Could Cure Hemophilia With Gene Therapy. For Real.
December, 9 2017
Power Women Entrepreneurs 2015
forbes.comArticle
Power Women Entrepreneurs 2015
March, 28 2016
Top Biotech Investors On The 2016 Midas List
forbes.comArticle
Top Biotech Investors On The 2016 Midas List
March, 23 2016
Were There 30 Million Cheaters On Ashley Madison, Or 10? How Estimates Get Out Of Hand
forbes.comArticle
Were There 30 Million Cheaters On Ashley Madison, Or 10? How Estimates Get Out Of Hand
September, 1 2015
Theranos' Elizabeth Holmes And Top Executives To Reimagine Healthcare At The Forbes Healthcare Summit
forbes.comArticle
Theranos' Elizabeth Holmes And Top Executives To Reimagine Healthcare At The Forbes Healthcare Summit
August, 31 2015
Alnylam, Medicines Co. Cholesterol Shot Exceeds Expectations, Lasts 140 Days
forbes.comArticle
Alnylam, Medicines Co. Cholesterol Shot Exceeds Expectations, Lasts 140 Days
August, 30 2015
Nine Explanations For Why The FDA Is Approving Almost Every New Drug Application
forbes.comArticle
Nine Explanations For Why The FDA Is Approving Almost Every New Drug Application
August, 25 2015
Sweet Victory: Eli Lilly's Jardiance Is First Diabetes Drug To Reduce Heart Attacks And Strokes
forbes.comArticle
Sweet Victory: Eli Lilly's Jardiance Is First Diabetes Drug To Reduce Heart Attacks And Strokes
August, 20 2015
Patient Death Does Not Augur Doom, But Kite Pharma Needs To Shut Its Big Mouth
forbes.comArticle
Patient Death Does Not Augur Doom, But Kite Pharma Needs To Shut Its Big Mouth
August, 17 2015
Carly Fiorina Is Against Vaccine Mandates But She's For Them But Also Against Them
forbes.comArticle
Carly Fiorina Is Against Vaccine Mandates But She's For Them But Also Against Them
August, 14 2015
Bill Gates And 13 Other Investors Pour $120 Million Into Revolutionary Gene-Editing Startup
forbes.comArticle
Bill Gates And 13 Other Investors Pour $120 Million Into Revolutionary Gene-Editing Startup
August, 10 2015
Shire's $30 Billion Baxalta Bid Faces Big Hurdles
forbes.comArticle
Shire's $30 Billion Baxalta Bid Faces Big Hurdles
August, 4 2015
Why Pharma Must Change Its Model
forbes.comArticle
Why Pharma Must Change Its Model
July, 30 2015
The Top Drug Launches Of All Time
forbes.comArticle
The Top Drug Launches Of All Time
July, 29 2015
Regeneron's George Yancopoulos Becomes Pharma's First Billionaire R&D Chief
forbes.comArticle
Regeneron's George Yancopoulos Becomes Pharma's First Billionaire R&D Chief
July, 28 2015
Allergan: Pharma's Biggest Dealmaker Is On The Hunt Again
forbes.comArticle
Allergan: Pharma's Biggest Dealmaker Is On The Hunt Again
July, 27 2015
Allergan To Buy Antidepressant Maker For $560 Million With Hopes Of Preventing Suicides
forbes.comArticle
Allergan To Buy Antidepressant Maker For $560 Million With Hopes Of Preventing Suicides
July, 26 2015
The Anthem-Cigna Deal Raises A Big Question For The U.S. Insurance Business
forbes.comArticle
The Anthem-Cigna Deal Raises A Big Question For The U.S. Insurance Business
July, 24 2015
The FDA Approves A Potent And Pricey Cholesterol-Lowering Shot
forbes.comArticle
The FDA Approves A Potent And Pricey Cholesterol-Lowering Shot
July, 24 2015
155 Angry Doctors Propose 7 Solutions For Terrifying Cancer Drug Prices
forbes.comArticle
155 Angry Doctors Propose 7 Solutions For Terrifying Cancer Drug Prices
July, 23 2015
Doctors Are Optimistic About Axovant's Experimental Alzheimer's Drug
forbes.comArticle
Doctors Are Optimistic About Axovant's Experimental Alzheimer's Drug
July, 22 2015
Exelixis Drug Slows Kidney Cancer In New Chance For Embattled Biotech
forbes.comArticle
Exelixis Drug Slows Kidney Cancer In New Chance For Embattled Biotech
July, 20 2015
Running A Few Tests On Theranos: Can Elizabeth Holmes Revolutionize Diagnostics?
forbes.comArticle
Running A Few Tests On Theranos: Can Elizabeth Holmes Revolutionize Diagnostics?
July, 15 2015
It's Time For The GOP To Embrace The Obamacare Exchanges
forbes.comArticle
It's Time For The GOP To Embrace The Obamacare Exchanges
June, 26 2015
Hope And Hype For New Type Of Antidepressant
forbes.comArticle
Hope And Hype For New Type Of Antidepressant
June, 24 2015
This Drug To Treat Double Chins Is a Perfect Fit For Botox-Maker Allergan. But Is It Too Pricey?
forbes.comArticle
This Drug To Treat Double Chins Is a Perfect Fit For Botox-Maker Allergan. But Is It Too Pricey?
June, 17 2015
FDA: Drug Companies Routinely Hide The Reasons Their Drugs Are Rejected From Investors
forbes.comArticle
FDA: Drug Companies Routinely Hide The Reasons Their Drugs Are Rejected From Investors
June, 12 2015
Study On Preventing College Rape Shows Us How We Should Run The World
forbes.comArticle
Study On Preventing College Rape Shows Us How We Should Run The World
June, 11 2015
Why Esperion Shares Are Down 18% Today
forbes.comArticle
Why Esperion Shares Are Down 18% Today
June, 10 2015
Live Blog: FDA Panel Votes To Approve Amgen's Cholesterol Drug Repatha
forbes.comArticle
Live Blog: FDA Panel Votes To Approve Amgen's Cholesterol Drug Repatha
June, 10 2015
How The New Cholesterol Drugs From Amgen And Regeneron Could Still Be Blockbusters
forbes.comArticle
How The New Cholesterol Drugs From Amgen And Regeneron Could Still Be Blockbusters
June, 10 2015
Breakthrough Cholesterol Drug Gets Ambivalent Endorsement
forbes.comArticle
Breakthrough Cholesterol Drug Gets Ambivalent Endorsement
June, 9 2015
Giant Study Boosts Januvia, Merck's $6 Billion Drug
forbes.comArticle
Giant Study Boosts Januvia, Merck's $6 Billion Drug
June, 8 2015
Company Aims To Democratize Genetic Tests At $475 A Pop
forbes.comArticle
Company Aims To Democratize Genetic Tests At $475 A Pop
June, 1 2015
Together, Genetic Test And Drug Unleash Immune System Against Tumors
forbes.comArticle
Together, Genetic Test And Drug Unleash Immune System Against Tumors
May, 29 2015
With A $1.2 Billion Hammer,  The FTC Closes Loophole To Prevent Generic Drugs
forbes.comArticle
With A $1.2 Billion Hammer,  The FTC Closes Loophole To Prevent Generic Drugs
May, 28 2015
Orexigen CEO Pledged To Keep Data Secret, But Not From Himself
forbes.comArticle
Orexigen CEO Pledged To Keep Data Secret, But Not From Himself
May, 20 2015
Botox Seems To Ease Depression
forbes.comArticle
Botox Seems To Ease Depression
May, 20 2015
The Message Of 'Mad Men': You Are Your Job
forbes.comArticle
The Message Of 'Mad Men': You Are Your Job
May, 18 2015
Authorship Stats
1Sites144Projects80,634Words
About
Matthew Herper is a writer who has produced content for forbes.com
Key Phrases
Chief Executive, Drug Administration, Health Care, Cancer Drug, Drug Companies, Heart Attacks, New York, Lung Cancer, Forbes Healthcare, Gene Therapy
© ClearVoice, Inc.